Leading the clinical development of
fibrinolysis without bleeding
to change the treatment paradigm for
ischemic stroke and heart attack.
Thrombolytic Science (TSI) is a private, clinical stage, vascular medicine & biotech company.
Our Focus
Current treatment options for patients experiencing a stroke or heart attack are limited and delay the
re-establishment of blood flow.
TSI is dedicated to transforming standards of care, by bringing a simple intravenous biotherapy to the patient, closer to the time of onset.
TSI’s bio-inspired solution is
-
A low dose, safer, dual thrombolytic Rx
-
Based on a clinically validated mechanism
-
To be given on suspicion of a stroke or heart attack
Clinical Trials
TSI recently completed a Phase 1 clinical study confirming the safety and tolerability of its novel tPA / HisproUK dual regimen.
TSI's dual regimen is currently being tested in two Phase 2 clinical trials, one in ischemic stroke patients, and an another in patients with acute myocardial infarction.
Science
tPA's biological role is limited to degrading the surface of the clot.
With TSI’s regimen, once this occurs, the small amount of tPA used is rapidly cleared from the blood flow. HisproUK, TSI's compound, exclusively targets the now degraded clot and dissolves it.
Should there be no degraded clot, as in the case of stroke mimics or a hemorrhagic stroke, HisproUK will remain safely in its inactive pro enzymatic form before being cleared in minutes from the blood flow.
TSI's thrombolytic regimen could therefore be given safely on simple suspicion of an ischemic stroke, as soon as possible after stroke onset.
Team
Management & Board of Directors
Advisory Board
Chairman of the Court,
London School of Hygiene &
Tropical Medicine
Non-Executive Chairman,
Cocoon Biotech
Professor of Medicine, Hematology
Adjunct Professor, Neurology,
Washington University
Senior Lecturer,
Harvard Medical School, Former Chief Medical Officer, Chairman & Founder, InfraReDx
1985 Nobel Peace Prize
President & CEO,
Baim Institute for Clinical Research
Professor of Medicine,
Harvard Medical School
Chairman & Founder, PERFUSE
News
October 30, 2019
September 5, 2018
NeurologyLive: Phase II Trial of HisproUK, Low-Dose tPA Dual Therapy for Ischemic Stroke Initiated
May 30, 2018
Thrombolytic Science to Participate in 2018 BIO International Conference
May 24, 2018
TSI presents at the 15th Anglo Nordic Life Science Investor Conference being held in London
December 14, 2017
TSI welcomes Annalisa Jenkins, MBBS, FRCP, as a non-executive board member
November 15, 2017
TSI appoints Michael Woehler, PhD, Chairman of the board
September 18, 2017
Publications
VIEW> Gurewich V. Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved. JACC 2016.
VIEW> Bogarty P, Brophy J. STEMI Treatment 2016: Is Outcome Improvement Stalling and If So, Why? DOI 2016.
VIEW> Pannell R, Li S, Gurewich V. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. PLoS One. 2015; 10(3):e0122018.
VIEW> Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS One. 2011; 6(7):e21999
